Pemvidutide treatment is associated with improvement in noninvasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial

pemvidutide (ALT-801) - Altimmune

Naim Alkhouri1; Shaheen Tomah2; John Suschak2; Jonathan Kasper2; M. Scot Roberts2; M. Scott Harris2; Sarah Browne2; Rohit Loomba3

Apr 2, 2024